$9.25
-0.31-3.24%
Últ. Act.: Oct 1, 6:57 PM
$9.33
-0.23-2.41%
Xeris Biopharma Holdings (XERS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Xeris Biopharma Holdings (XERS) publicó su última previsión de agosto 6, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $385M - $390M para el período.
En comparación con la previsión anterior, Xeris Biopharma Holdings mantenido redujo su previsión de ingresos desde un rango anterior de $380M - $390M.
Xeris Biopharma Holdings ha emitido 22 actualizaciones de orientación entre el marzo 8, 2023 y el agosto 6, 2026. During this period, the company raised its outlook 14 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.01 | $-0.01 | $0.04 | $0.01 |
| Actual | $0.00 | $0.01 | $0.06 | $0.00 |
| Surprise | -100.0% | +200.0% | +50.0% | -100.0% |
| Revenue | ||||
| Estimate | $90.4M | $80.0M | $84.2M | $74.3M |
| Actual | $92.1M | $83.1M | $85.8M | $74.4M |
| Surprise | +1.84% | +3.91% | +1.94% | +0.17% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.01 | $0.05 | $0.03 | $0.09 |
| Revenue | ||||
| Consensus | $101.4M | $110.7M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $0 | $0.01 | -100.0 % |
| Q1 | May 7, 2026 | $0.01 | $-0.01 | 200.0 % |
| Q4 | Mar 2, 2026 | $0.06 | $0.04 | 50.0 % |
| Q3 | Nov 6, 2025 | $0 | $0.01 | -100.0 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $92.10M | $90.43M | 1.84 % |
| Q1 | May 7, 2026 | $83.13M | $80.00M | 3.91 % |
| Q4 | Mar 2, 2026 | $85.81M | $84.17M | 1.94 % |
| Q3 | Nov 6, 2025 | $74.38M | $74.26M | 0.17 % |